GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Bio Therapeutics Co Ltd (ROCO:6892) » Definitions » EV-to-EBITDA

Taiwan Bio Therapeutics Co (ROCO:6892) EV-to-EBITDA : -16.26 (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Taiwan Bio Therapeutics Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Taiwan Bio Therapeutics Co's enterprise value is NT$2,373.88 Mil. Taiwan Bio Therapeutics Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-145.97 Mil. Therefore, Taiwan Bio Therapeutics Co's EV-to-EBITDA for today is -16.26.

The historical rank and industry rank for Taiwan Bio Therapeutics Co's EV-to-EBITDA or its related term are showing as below:

ROCO:6892' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.59   Med: -14.25   Max: -11.77
Current: -16.26

During the past 5 years, the highest EV-to-EBITDA of Taiwan Bio Therapeutics Co was -11.77. The lowest was -25.59. And the median was -14.25.

ROCO:6892's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.54 vs ROCO:6892: -16.26

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Taiwan Bio Therapeutics Co's stock price is NT$37.80. Taiwan Bio Therapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-3.875. Therefore, Taiwan Bio Therapeutics Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Taiwan Bio Therapeutics Co EV-to-EBITDA Historical Data

The historical data trend for Taiwan Bio Therapeutics Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Bio Therapeutics Co EV-to-EBITDA Chart

Taiwan Bio Therapeutics Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - - -12.97 -14.59

Taiwan Bio Therapeutics Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial - - -12.97 - -14.59

Competitive Comparison of Taiwan Bio Therapeutics Co's EV-to-EBITDA

For the Biotechnology subindustry, Taiwan Bio Therapeutics Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiwan Bio Therapeutics Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Taiwan Bio Therapeutics Co's EV-to-EBITDA falls into.



Taiwan Bio Therapeutics Co EV-to-EBITDA Calculation

Taiwan Bio Therapeutics Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2373.876/-145.97
=-16.26

Taiwan Bio Therapeutics Co's current Enterprise Value is NT$2,373.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Bio Therapeutics Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-145.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taiwan Bio Therapeutics Co  (ROCO:6892) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Taiwan Bio Therapeutics Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=37.80/-3.875
=At Loss

Taiwan Bio Therapeutics Co's share price for today is NT$37.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Bio Therapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-3.875.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Taiwan Bio Therapeutics Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Taiwan Bio Therapeutics Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiwan Bio Therapeutics Co (ROCO:6892) Business Description

Traded in Other Exchanges
N/A
Address
No. 18, Lane 120, Hu Road, Section 1, 6th Floor, Neihu District, Taipei, TWN
Taiwan Bio Therapeutics Co Ltd is a regenerative medicine company specializing in the development of new cell medicines. It provides cell product process development and foundry (CDMO/CMO) services.

Taiwan Bio Therapeutics Co (ROCO:6892) Headlines

No Headlines